Glendon E. French is the Chief Executive Officer at Pulmonx Corp, a leading medical technology company focused on developing innovative treatments for patients with severe lung disease. With a robust background in the medical device industry, French has been instrumental in driving Pulmonx's growth and success. Before joining Pulmonx, he held various leadership positions at prominent companies such as Intuitive Surgical, where he served as the Executive Vice President of Strategy and Operations. His strategic vision and operational expertise have been key factors in his ability to lead Pulmonx through significant milestones, including the company's initial public offering in 2020. At Pulmonx, French oversees the company's overall operations and strategic direction, guiding the development and commercialization of groundbreaking technologies like the Zephyr Valve, a minimally invasive treatment for severe emphysema. Under his leadership, Pulmonx has expanded its global presence and strengthened its commitment to improving patient outcomes. French's dedication to innovation and patient care is evident in the company's ongoing research and development efforts, which aim to address unmet needs in the treatment of chronic lung diseases. His leadership has not only positioned Pulmonx as a leader in its field but has also fostered a culture of excellence and collaboration within the organization.